UNSPSC 51422108: Mometasone

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28Cl2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8HR4QJ6DW8, chemically known as pregna-1,4-diene-3,20-dione, 9,21-dichloro-11,17-dihydroxy-16-methyl-, (11beta,16alpha)- but generally known as mometasone, which bears US NIH Compound Identifier 123620. European Medicines Agency schedules Mometasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09045MIG.

UNSPSC 51422108 Mometasone is a Commodity code that in recent state and local activity covers the procurement of pharmaceutical products and related health-system supplies, though the solicitations tagged under this code diverge significantly from the mometasone name. Seminole County, Florida and the Texas Health and Human Services Commission have posted opportunities that reflect a broader pattern of state and local health agencies buying naloxone, drug deactivation systems, and pharmaceutical benefit program capabilities rather than the specific corticosteroid the code nominally describes. The issuing bodies include county health departments and state health agencies managing community health initiatives and pharmacy benefit programs. Work under the code centers on procurement of pharmaceutical inventory for emergency response and public health use, as well as vendor capabilities for direct-to-manufacturer prescription fulfillment models that bypass traditional pharmacy benefit managers and group purchasing organizations.

Recent activity appears concentrated in Florida and Texas. Seminole County issued IFB 60459723LAS on June 30, 2026 (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, on a two-year initial contract with one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to solicit vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, seeking information on vendors' experience with self-insured employers and state agencies and their ability to implement negotiated net pricing and outcomes-based agreements. The Seminole County procurement requires electronic bid submission through the county e-Procurement Portal, E-Verify compliance, and drug-free workplace certification; the Texas RFI functions as early-stage market intelligence to inform future formal solicitation strategy. Neither opportunity specifies explicit set-aside or disadvantaged-enterprise designations.